PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.

Sponsor
University of Texas Southwestern Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03942952
Collaborator
(none)
160
1
55.3
2.9

Study Details

Study Description

Brief Summary

Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM). The symptoms of these conditions are quite variable from patient to patient, but can include motor, sensory, visual, gait and cognitive changes. Conventional MRI can be used to look for new anatomic changes, but fails to measure underlying biochemical changes in brain tissue. The purposes of this study are to identify the biologic and anatomic correlations between cognitive profiles and disease activity using MRI imaging techniques.

Detailed Description

Pediatric patients (age 12 to 21 inclusive) with a diagnosis of multiple sclerosis, ADEM, anti-MOG mediated demyelinating disease as well as healthy controls will be recruited to undergo clinical testing. The study visits will include neuropsychological testing, optical coherence tomography (OCT) and MRI on both the 3T and 7T magnet. Subjects will be asked to undergo two study visits separated by 12 months to 18 months. Each study visit will have the same neuropsychological, OCT, and research MRI examinations.

Study Design

Study Type:
Observational
Anticipated Enrollment :
160 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Actual Study Start Date :
Oct 22, 2019
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
May 31, 2024

Arms and Interventions

Arm Intervention/Treatment
CNS demyelinating diagnosis

Diagnosis of CNS demyelinating disorder: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, anti-MOG antibody, Optic Neuritis. 3T and 7T MRI Neuropsychological testing Optical Coherence Tomography Questionnaires: Quality of Life and Behavior scales Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one to year and a half year later

Healthy Control

3T and 7T MRI Neuropsychological testing Optical Coherence Tomography Questionnaires: Quality of Life and Behavior scales Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year to a year and a half later

Outcome Measures

Primary Outcome Measures

  1. MRI Brain without contrast [10-14 months]

    3T MRI

  2. MRI Brain without contrast [10-14 months]

    7T MRI

  3. Change in Score of Delis-Kaplan Executive Function System (D-KEFS) Color [10-14 months]

    Executive Functioning

  4. Change in Score of Word Interference Test (CWIT) [10-14 months]

    Executive Functioning

  5. Change in Score of Symbol Digit Modalities (SDMT)- Oral Version [10-14 months]

    Processing Speed

  6. Change in Score of Beery-Buktencia Developmental Test of Visual-Motor Integration, Sixth Edition (VMI-6) [10-14 months]

    Visual-Motor Integration

  7. Change in Score of Wechsler Intelligence Scale for Children-5th edition (WISCV) [10-14 months]

    Simple Auditory Attention

  8. Change in Score of Wechsler Adult Intelligence Scale-Fourth edition (WAIS-IV) Digits Forward [10-14 months]

    Simple Auditory Attention

  9. Change in Score of WISC-V or WAIS-IV Digits Backward [10-14 months]

    Working Memory

  10. Change in Score of California Verbal Learning Test- Children's Version (CVLT-C) or California Verbal Learning Test-Second Edition (CVLT-II) [10-14 months]

    Verbal Learning and Memory

  11. Change i Score of D-KEFS Letter and Category Fluency [10-14 months]

    Verbal Fluency

  12. Change in Score of WASI-II [10-14 months]

    Estimate of IQ

  13. Change in Score of Woodcock-Johnson Tests of Achievement Letter Word identification [10-14 months]

    Basic Reading Skill

  14. Change in Score of Reading Fluency [10-14 months]

    Reading Speed

  15. Change in Score of Calculation [10-14 months]

    Math Calculation Skills

  16. Change in Score of Math Fluency [10-14 months]

    Math Speed

  17. Change in Score of Word Attack [10-14 months]

    Phoneme/Grapheme Knowledge

  18. Change in Score of Grooved Pegboard [10-14 months]

    Bilateral Fine Motor Speed and Dexterity

  19. Change in Score of Trail Making Test, Part A and B [10-14 months]

    Simple and complex Attention

  20. Change in Score of Conners Continuous Performance Test 3rd Edition [10-14 months]

    Sustained Attention and Behavioral Inhibition

Secondary Outcome Measures

  1. Change in Examination of Optical Coherence Tomography [10-14 months]

    Eye examination

  2. Change in PROMIS Mobility score [10-14 months]

    Patient Reported Outcomes Measures: Mobility, walking

  3. Change in PROMIS Pain score [10-14 months]

    Patient Reported Outcomes Measures: overall pain level

  4. Change in PROMIS Peer relationship score [10-14 months]

    Patient Reported Outcomes Measures: Peer relationships

  5. Change in PROMIS Stress score [10-14 months]

    Patient Reported Outcomes Measures: Psychological stress

  6. Change in PROMIS Upper extremity movement score [10-14 months]

    Patient Reported Outcomes Measures: Upper extremity movement

  7. Change in score of 25 foot timed walk [10-14 months]

    Walking speed

  8. Change in score of 6 minute timed walk [10-14 months]

    Walking Distance

  9. Change in score of Hauser Ambulation Index [10-14 months]

    Functional walking assessment

  10. Change in score of Multiple Sclerosis Functional Capacity (MSFC) [10-14 months]

    Hand and Eye coordination, Memory test

  11. Change in score of Modified Rankin Scale [10-14 months]

    Disability scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Diagnosis of Multiple Sclerosis , ADEM, anti-MOG antibody associated CNS demyelination

  2. Age 12 to 21 inclusive at time of enrollment

  3. Ability of parent or legal guardian to provide informed consent if participant is under 18.

  4. Ability of patients age 12-17 to give assent

  5. Completion of the signed HIPPA authorization form by a parent or legal guardian or by participants (18 years of age).

Exclusion Criteria:
  1. Known history of traumatic brain injury that required medical care

  2. Non-English speaking (based on standardized neuropsychological testing and questionnaires)

  3. Claustrophobic, the presence of metallic braces, implants or medical devices that are unsafe at 3T or 7T and/or interfere with the MRI/MRS signals

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Texas Southwestern Dallas Texas United States 75390

Sponsors and Collaborators

  • University of Texas Southwestern Medical Center

Investigators

  • Principal Investigator: Benjamin Greenberg, MD. MHS, University Texas Southwestern

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Benjamin Greenberg, Professor, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT03942952
Other Study ID Numbers:
  • STU-2019-0491
First Posted:
May 8, 2019
Last Update Posted:
Jul 22, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Benjamin Greenberg, Professor, University of Texas Southwestern Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 22, 2022